Becton Dickinson 경영진

경영진 기준 점검 4/4

Becton Dickinson CEO는 Tom Polen, Apr2017 에 임명되었습니다 의 임기는 6.25 년입니다. 총 연간 보상은 $17.13M, 8.1% 급여 및 91.9% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $15.77M 가치에 해당하는 회사 주식의 0.036% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 3.6 년과 7 년입니다.

핵심 정보

Tom Polen

최고경영자

US$17.1m

총 보수

CEO 급여 비율	8.15%
CEO 재임 기간	9yrs
CEO 지분 보유율	0.04%
경영진 평균 재임 기간	3.6yrs
이사회 평균 재임 기간	7yrs

최근 경영진 업데이트

Recent updates

Some Investors May Be Willing To Look Past Becton Dickinson's (NYSE:BDX) Soft Earnings

Nov 16

Becton Dickinson (NYSE:BDX) Has Announced That It Will Be Increasing Its Dividend To $1.05

Nov 09

Becton, Dickinson and Company: It's Wait And See For Me

Apr 27

Becton Dickinson Could Be Cure To Demand For Medtech Supplies, With Robust Pipeline

Mar 30

Beckton, Dickinson: Hold, Momentum Is Gaining, Just Need More Growth

Jan 20

CEO 보수 분석

Tom Polen의 보수는 Becton Dickinson의 수익에 비해 어떻게 변했나요?
날짜	총 보수	급여	회사 수익
Dec 31 2025	n/a	n/a	US$2b
Sep 30 2025	US$17m	US$1m	US$2b
Jun 30 2025	n/a	n/a	US$2b
Mar 31 2025	n/a	n/a	US$1b
Dec 31 2024	n/a	n/a	US$2b
Sep 30 2024	US$17m	US$1m	US$2b
Jun 30 2024	n/a	n/a	US$1b
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	n/a	n/a	US$1b
Sep 30 2023	US$17m	US$1m	US$1b
Jun 30 2023	n/a	n/a	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	n/a	n/a	US$1b
Sep 30 2022	US$17m	US$1m	US$2b
Jun 30 2022	n/a	n/a	US$1b
Mar 31 2022	n/a	n/a	US$1b
Dec 31 2021	n/a	n/a	US$1b
Sep 30 2021	US$14m	US$1m	US$2b
Jun 30 2021	n/a	n/a	US$1b
Mar 31 2021	n/a	n/a	US$1b
Dec 31 2020	n/a	n/a	US$2b
Sep 30 2020	US$12m	US$952k	US$245m
Jun 30 2020	n/a	n/a	US$786m
Mar 31 2020	n/a	n/a	US$923m
Dec 31 2019	n/a	n/a	US$760m
Sep 30 2019	US$6m	US$900k	US$1b

보상 대 시장: Tom의 총 보수(USD17.13M)는 US 시장에서 비슷한 규모 기업의 평균(USD14.14M) 수준입니다.

보상과 수익: Tom의 보상은 지난 1년 동안 회사 실적과 일치했습니다.

CEO

Tom Polen (52 yo)

9yrs

재임 기간

US$17,129,139

보수

Mr. Thomas E. Polen, Jr., also known as Tom, serves as Chief Executive Officer and Director at Becton, Dickinson and Company since January 28, 2020. Mr. Polen served as an Independent Director at Walgreens...

리더십 팀

이름	직위	재임 기간	보수	지분
Thomas Polen	President	9yrs	US$17.13m	0.036% $ 15.8m
Michael Garrison	Executive VP & President of Medical Segment and BioPharma Systems Segments	3.6yrs	US$3.65m	0.0043% $ 1.9m
Richard Byrd	Executive VP & President of Interventional Segment	3.6yrs	US$3.40m	0.0011% $ 509.7k
Michael Feld	Executive VP & Chief Revenue Officer	less than a year	US$4.10m	0.0075% $ 3.3m
Vitor Roque	Senior VP of Business Finance & Interim CFO	less than a year	데이터 없음	0.0023% $ 1.0m
Pamela Spikner	Senior VP	1.3yrs	데이터 없음	0.0012% $ 518.5k
Elizabeth McCombs	Executive VP & CTO	5yrs	데이터 없음	데이터 없음
Joseph Smith	Senior VP & Chief Scientific Officer	4.4yrs	데이터 없음	데이터 없음
Denise Fleming	Executive VP of Technology & Global Services and Chief Information Officer	4.3yrs	데이터 없음	데이터 없음
Shawn Bevec	Senior Vice President of Investor Relations	less than a year	데이터 없음	데이터 없음
Claudia Curtis	Senior VP	no data	데이터 없음	데이터 없음
Lanesha Minnix	Executive VP & General Counsel	less than a year	데이터 없음	데이터 없음

3.6yrs

평균 재임 기간

49yo

평균 나이

경험이 풍부한 관리: BDX의 경영진은 경험이 있음으로 간주됩니다(평균 재임 3.6 년).

이사회 구성원

이름	직위	재임 기간	보수	지분
Thomas Polen	President	6.3yrs	US$17.13m	0.036% $ 15.8m
Robert Eckert	Lead Independent Director	9.6yrs	US$365.17k	0.0037% $ 1.6m
Timothy Ring	Independent Director	9.3yrs	US$335.17k	0.022% $ 9.6m
Jeffrey Henderson	Independent Director	7.7yrs	US$360.17k	0.0032% $ 1.4m
Christopher Ian Jones	Independent Director	15.8yrs	US$365.17k	0.0085% $ 3.8m
Bertram Scott	Independent Director	23.6yrs	US$375.17k	0.013% $ 5.7m
Gregory Hayes	Independent Director	1.1yrs	US$223.45k	0.0019% $ 819.9k
Catherine Burzik	Independent Director	13.3yrs	US$360.17k	0.0033% $ 1.5m
William Brown	Independent Director	4.2yrs	US$335.17k	0.0016% $ 726.8k
Robert Huffines	Independent Director	less than a year	데이터 없음	0% $ 0
Carrie Byington	Independent Director	4.5yrs	US$345.17k	0.0018% $ 780.0k
Joanne Waldstreicher	Independent Director	2.8yrs	US$336.17k	0.00048% $ 212.7k

7.0yrs

평균 재임 기간

63.5yo

평균 나이

경험이 풍부한 이사회: BDX의 이사회는 경험이 있음으로 간주됩니다(평균 재임 7 년).

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/04/23 22:10
종가	2026/04/23 00:00
수익	2025/12/31
연간 수익	2025/09/30

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Becton, Dickinson and Company는 35명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
David Toung	Argus Research Company
Adam Feinstein	Barclays
Matthew Miksic	Barclays

Becton Dickinson 경영진

경영진 기준 점검 4/4

핵심 정보

최근 경영진 업데이트

Becton, Dickinson and Company Appoints Lanesha Minnix as Executive Vice President and General Counsel, Effective March 16, 2026

Becton, Dickinson and Company Announces Steeping Down of Claire M. Fraser from Its Board of Directors

BD Appoints Shawn Bevec as Senior Vice President of Investor Relations, Effective January 20, 2026

Becton, Dickinson and Company, Annual General Meeting, Jan 27, 2026

Becton, Dickinson and Company Appoints Robert "Robbie" Huffines and Jacqueline "Jacky" Wright to Its Board of Directors, Effective December 1, 2025

Director recently bought US$1.0m worth of stock

Recent updates

Becton, Dickinson: Value Or Overvalued Even Now?

Becton, Dickinson and Company to Report Q2, 2026 Results on May 07, 2026

Becton Dickinson and Company Announces Clinical Findings for BD Purewick Urine Collection System

BD Delivers Next-Generation TIPS Innovation to Advance Portal Hypertension Care Across the European Union

Becton, Dickinson and Company Launches BD Pyxis Pro Dispensing Solution And BD Incada Connected Care Platform In Europe

Upcoming dividend of US$1.05 per share

Becton, Dickinson and Company Receives 510(K) Clearance from the U.S. Food and Drug Administration for the Surgiphor™? 1000Ml

Now 21% undervalued after recent price drop

Bd Announces the Launch of the Bd Vacutainer Urine Complete Cup Kit

Becton, Dickinson and Company Appoints Lanesha Minnix as Executive Vice President and General Counsel, Effective March 16, 2026

Investor sentiment deteriorates as stock falls 15%

Price target decreased by 7.8% to US$195

Now 25% undervalued after recent price drop

Waters Corporation (NYSE:WAT) completed the acquisition of Biosciences and Diagnostics Solutions Business of Becton, Dickinson and Company (NYSE:BDX) in a transaction valued at $18.8 billion.

Becton, Dickinson and Company Announces Steeping Down of Claire M. Fraser from Its Board of Directors

Becton Dickinson (NYSE:BDX) Will Pay A Dividend Of $1.05

Fourth quarter dividend of US$1.05 announced

Becton, Dickinson and Company (NYSE:BDX) announces an Equity Buyback for $250 million worth of its shares.

Becton, Dickinson and Company to Report Q1, 2026 Results on Feb 09, 2026

BD Helps Scientists Advance Immunology and Cancer Research with AI-Powered Insights and Automation

Becton, Dickinson and Company Receives FDA 510(k) Clearance for EnCor EnCompass Breast Biopsy and Tissue Removal System

BD Appoints Shawn Bevec as Senior Vice President of Investor Relations, Effective January 20, 2026

Becton, Dickinson and Company, Annual General Meeting, Jan 27, 2026

Becton, Dickinson and Company Expands BD Max System Menu with New IVDR-Certified VIASURE Assays in Partnership with Certest Biotec

BD Launches New Cell Analyzer Configurations to Bring Cutting-Edge Capabilities to Labs of All Sizes

Upcoming dividend of US$1.05 per share

Bd Surgiphor™? Surgical Wound Irrigation System Expands to Europe to Help Hospitals Improve Patient Safety

Becton Dickinson's (NYSE:BDX) Dividend Will Be Increased To $1.05

Becton, Dickinson and Company Appoints Robert "Robbie" Huffines and Jacqueline "Jacky" Wright to Its Board of Directors, Effective December 1, 2025

Some Investors May Be Willing To Look Past Becton Dickinson's (NYSE:BDX) Soft Earnings

Becton, Dickinson and Company Introduces PureWick Portable Collection System

Becton Dickinson (NYSE:BDX) Has Announced That It Will Be Increasing Its Dividend To $1.05

Fourth quarter dividend increased to US$1.05

New minor risk - Earnings quality

Full year 2025 earnings: EPS misses analyst expectations

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on December 31, 2025

Becton, Dickinson and Company Achieves Milestone in AGILITY Study of Revello Vascular Covered Stent for Treatment of Peripheral Artery Disease

BD Receives FDA 510(k) Clearance and CE-IVDR Certification for High-Throughput Enteric Bacterial Panels on BD COR System

Becton, Dickinson and Company Announces New Self- Collection Solution for HPV Testing in Markets Outside the United States

Bd Introduces the Bd Incada™? Connected Care Platform

Becton, Dickinson and Company Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Fiscal Ended September 30, 2025

Becton, Dickinson and Company Reaches Major Milestone for Rotarex™? Catheter System with First Patient Enrolled in XTRACT™? Registry to Advance Real-World Evidence in Peripheral Artery Disease

Bd Marks 1,000Th Bd Rhapsody System, Driving Scientific Breakthroughs Via Single-Cell Multiomics

Upcoming dividend of US$1.04 per share

Director recently bought US$1.0m worth of stock

Third quarter 2025 earnings: EPS exceeds analyst expectations

Becton, Dickinson and Company Revises Its Earnings Guidance for the Year 2025

Becton, Dickinson and Company Submits Application to FDA for At-Home Hpv Test with Self-Collection Swab and High-Tech Laboratory Robotics

Becton, Dickinson and Company Receives FDA 510(k) Clearance for Rapid Point-Of-Care COVID-19 Test

Second quarter dividend of US$1.04 announced

Becton, Dickinson and Company Announces First Pharma-Sponsored Clinical Trial Using BD Libertas Wearable Injector Technology for Biologic Drugs

Waters Corporation (NYSE:WAT) entered into a definitive agreement to acquire Biosciences and Diagnostics Solutions Business of Becton Dickinson and Company in a transaction valued at $17.5 billion.

BD Appoints Bilal Muhsin as Executive Vice President and President of Future Connected Care Segment, Effective July 2

Consensus EPS estimates fall by 12%

Upcoming dividend of US$1.04 per share

Becton, Dickinson and Company to Initiate Real-World Patient Data Registry for the Rotarex™? Atherectomy System in Treatment of Peripheral Artery Disease

Retractable Technologies, Inc. Enters Settlement Agreement with Becton, Dickinson and Company

Becton, Dickinson and Company Announces Cancer Patients Face Elevated Risk of Carrying Antimicrobial Resistant 'Superbugs'

Becton, Dickinson and Company Launches Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies

Consensus EPS estimates fall by 10%

Price target decreased by 16% to US$231

Second quarter dividend of US$1.04 announced

Becton, Dickinson and Company Updates Earnings Guidance for the Fiscal Year 2025

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 30, 2025

Becton, Dickinson and Company: It's Wait And See For Me

Becton, Dickinson and Company Launches Industry-First Bioabsorbable Mesh Designed for Umbilical Hernia Repair

Becton, Dickinson and Company Launches Next Generation Hemodynamic Monitoring Solution Providing Clinicians with Ai-Driven Clinical Decision Support

Becton Dickinson Could Be Cure To Demand For Medtech Supplies, With Robust Pipeline

Becton, Dickinson and Company Appoints Gregory J. Hayes to Board of Directors, Effective March 26, 2025